Bristol-Myers Squibb: Lymphoma, Follicular trials

The registry lists 18 Lymphoma, Follicular studies with Bristol-Myers Squibb as lead sponsor. 3 are open to participants now and 4 have results posted.

Phase 1 7Phase 2 4Phase 3 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in ItalyRecruitingNCT07256015
• A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingNCT06911502Phase 3
• A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingRecruitingNCT06794268
• A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedNCT03310619Phase 1/2Results posted
• Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)CompletedNCT02038946Phase 2Results posted
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.CompletedNCT01996865Phase 3Results posted
• Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaCompletedNCT01476787Phase 3Results posted
• Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCompletedNCT06535399Phase 1
• A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaActive, not recruitingNCT06425302Phase 2
• Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCompletedNCT06425198Phase 1
• A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic ImpairmentCompletedNCT06352528Phase 1
• A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaWithdrawnNCT06313996Phase 3
• A Rollover Study of CC-122Active, not recruitingNCT05688475Phase 1
• Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort StudyTerminatedNCT04982471
• A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruitingNCT04245839Phase 2
• A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in KoreaCompletedNCT04036448
• A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaCompletedNCT02343536Phase 1
• Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedNCT02031419Phase 1